- Investing Ideas
- /
- Global Undervalued Stocks Based On Cash Flows
Global Undervalued Stocks Based On Cash Flows
Results
963
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
963 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
LUMI | NOK 12.90 | 11.2% | -14.0% | NOK 699.9m | n/a | PS1.8x | E112.6% | 0% | Consumer Services | ||
ELK | NOK 20.48 | 2.8% | -19.2% | NOK 13.0b | NOK 25.60 | PB0.5x | E92.8% | 0% | Materials | ||
3022 | CN¥13.73 | -4.0% | -44.6% | CN¥18.3b | n/a | PE52.3x | E29.9% | 0.6% | Materials | ||
4480 | JP¥3,565.00 | -0.6% | -34.5% | JP¥115.7b | JP¥5,800.00 | PE43.3x | E28.7% | n/a | Healthcare | ||
ARCAD | €59.30 | -0.9% | 55.2% | €5.4b | €65.36 | PE33.4x | E20.7% | 1.4% | Commercial Services | ||
ALNY | US$247.61 | 3.1% | 30.5% | US$30.8b | US$248.46 | PS15.6x | E63.6% | n/a | Pharmaceuticals & Biotech | ||
2755 | CN¥9.43 | -4.9% | 10.4% | CN¥9.1b | CN¥13.00 | PS5.6x | E90.7% | 0% | Pharmaceuticals & Biotech | ||
2190 | HK$10.86 | 7.1% | -9.3% | HK$3.5b | HK$15.25 | PS6.2x | E79.3% | n/a | Healthcare | ||
SVEG | NOK 131.60 | 4.9% | 27.3% | NOK 14.2b | NOK 139.80 | PB0.6x | E20.6% | 5.7% | Banks | ||
CXB | CA$1.81 | 3.4% | 25.7% | CA$1.4b | CA$2.85 | PE16.1x | E45.2% | n/a | Materials | ||
PSAN | €21.90 | 3.8% | -31.3% | €340.7m | €30.18 | PS1.3x | E59.8% | 1.8% | Software | ||
INPST | €16.36 | -0.2% | 65.3% | €8.1b | €17.22 | PE44.7x | E27.9% | n/a | Transportation | ||
APP | US$83.68 | 3.0% | 222.8% | US$27.9b | US$93.24 | PE46.3x | E24.6% | n/a | Software | ||
FLNC | US$15.88 | -14.6% | -39.3% | US$2.9b | US$28.83 | PB4.9x | E100.7% | n/a | Capital Goods | ||
A214370 | ₩22,450.00 | -3.6% | -53.4% | ₩1.1t | ₩24,000.00 | PE31.2x | E24.3% | 2.9% | Pharmaceuticals & Biotech | ||
LSL | UK£3.28 | 0.9% | 21.0% | UK£335.8m | UK£3.69 | PE41.6x | E33.3% | 3.5% | Real Estate Management and Development | ||
NAPA | US$7.18 | 2.7% | -44.0% | US$1.0b | US$9.67 | PE16.9x | E24.9% | n/a | Food, Beverage & Tobacco | ||
VEE | AU$1.78 | 2.6% | 327.7% | AU$241.0m | AU$2.25 | PE41.7x | E20.9% | 0.9% | Capital Goods | ||
CXO | AU$0.085 | -5.6% | -91.2% | AU$181.6m | n/a | PB0.6x | E69.5% | n/a | Materials | ||
688513 | CN¥33.62 | -3.9% | -9.8% | CN¥5.9b | CN¥51.02 | PE24.4x | E22.0% | 1.2% | Pharmaceuticals & Biotech | ||
ENT | UK£6.19 | -6.3% | -51.0% | UK£4.0b | UK£10.14 | PB1.7x | E96.7% | 2.9% | Consumer Services | ||
HNVR | US$16.21 | -1.6% | -9.9% | US$118.6m | US$18.50 | PB0.6x | E20.9% | 2.5% | Banks | ||
7030 | ر.س11.22 | -2.1% | -18.8% | ر.س10.1b | ر.س12.88 | PE51.4x | E43.0% | 4.5% | Telecom | ||
4071 | JP¥1,884.00 | -2.8% | -44.8% | JP¥77.5b | JP¥3,260.00 | PE27.2x | E21.0% | 0.8% | Software |